Inventor · disambiguated record
David J. Mangelsdorf
Also filed as: MANGELSDORF DAVID J · MANGELSDORF DAVID JOHN
21 granted patents·3 pending applications·444 citations·filing 1994–2023
96Inventor score
Files withSALK INST FOR BIOLOGICAL STUDI11UNIV TEXAS8LIGAND PHARM INC3BOARD OF REGENTS UNIV OF TEXAS SYSTEM1HUGHES HOWARD MED INST1
Top patents by PatentIndex Score
24 records- 0192US5710004AMethods of using novel steroid hormone orphan receptorsSALK INST FOR BIOLOGICAL STUDI·Filed 1996·Granted Jan 20, 1998·99 cites·16 claims
- 0285US5723329ADNA encoding retinoid receptor X (RXR) alpha and gamma; corresponding vectors and host cellsSALK INST FOR BIOLOGICAL STUDI·Filed 1994·Granted Mar 3, 1998·77 cites·17 claims
- 0385US5571696AReceptorsSALK INST FOR BIOLOGICAL STUDI·Filed 1994·Granted Nov 5, 1996·57 cites·14 claims
- 0480US7825269B2Ligands for nematode nuclear receptors and uses thereofUNIV TEXAS·Filed 2007·Granted Nov 2, 2010·7 cites·2 claims
- 0578US6893830B1Method of screening oxysterol activation of LXRαUNIV TEXAS·Filed 2000·Granted May 17, 2005·18 cites·12 claims
- 0676US7056954B2Means for the modulation of processes mediated by retinoid receptors and compounds useful thereforLIGAND PHARM INC·Filed 2003·Granted Jun 6, 2006·3 cites·2 claims
- 0776US5990163ASelective modulation of processes mediated by retinoid X receptors, and compounds useful thereforSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Nov 23, 1999·51 cites·16 claims
- 0876US5696233AOrphan steroid hormone receptorsSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Dec 9, 1997·24 cites·20 claims
- 0969US12178848B2Methods and compositions for the treatment of exocrine pancreatic insufficiencyUNIV TEXAS·Filed 2022·Granted Dec 31, 2024·0 cites·16 claims
- 1065US10117878B2Ligands for nematode nuclear receptors and uses thereofBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2012·Granted Nov 6, 2018·1 cites·9 claims
- 1165US8007994B2Compositions and methods of modulating cholesterol metabolismUNIV TEXAS·Filed 2004·Granted Aug 30, 2011·9 cites·10 claims
- 1263US2006211768A1Means for the modulation of processes mediated by retinoid receptors and compounds useful thereforLIGAND PHARM INC·Filed 2005·Application pending·0 cites
- 1360US6506917B1Compounds and compositions useful for modulation of processes mediated by RXRSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Jan 14, 2003·18 cites·26 claims
- 1459US11318186B2Use of FGF21 in methods of increasing exocrine pancreatic secretionUNIV TEXAS·Filed 2017·Granted May 3, 2022·0 cites·15 claims
- 1558US2025195615A1Methods and compositions for the treatment of alcohol toxicityUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1657US5968989AMeans for the modulation of processes mediated by retinoid receptors and compounds useful thereforSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Oct 19, 1999·17 cites·28 claims
- 1755US5747661ARetinoid-inducible response elementsHUGHES HOWARD MED INST·Filed 1995·Granted May 5, 1998·19 cites·5 claims
- 1852US5932622AMethod for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acidSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Aug 3, 1999·14 cites·2 claims
- 1949US2011028443A1Ligands for nematode nuclear receptors and uses thereofUNIV TEXAS·Filed 2010·Application pending·0 cites
- 2048US5707800ARetinoic acid response elements and assays employing sameSALK INST FOR BIOLOGICAL STUDI·Filed 1994·Granted Jan 13, 1998·9 cites·72 claims
- 2147US7501487B1Retinoid receptor compositions and methodsSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Mar 10, 2009·5 cites·6 claims
- 2245US6835866B1Compositions and methods of modulating cholesterol metabolismUNIV TEXAS·Filed 1999·Granted Dec 28, 2004·12 cites·21 claims
- 2340US6576676B1Means for the modulation of processes mediated by retinold receptors and compounds useful thereforSALK INST FOR BIOLOGICAL STUDI·Filed 1999·Granted Jun 10, 2003·4 cites·1 claims
- 2431US6992108B1Means for the modulation of processes mediated by retinoid receptors and compounds useful thereforLIGAND PHARM INC·Filed 1995·Granted Jan 31, 2006·0 cites·1 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →